Literature DB >> 9932604

Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations.

M M Pacheco1, M Mourão, E B Mantovani, I N Nishimoto, M M Brentani.   

Abstract

The purpose of this study was to investigate the association among matrix metalloproteinases (gelatinases A and B, stromelysin-3 (ST3) and matrilysin) mRNAs expressed in primary breast carcinomas and standard prognostic parameters and clinical outcome. mRNA levels were determined by Northern analysis in samples of 81 breast cancer patients (median follow-up, 40 months) and 27 samples of uninvolved adjacent breast tissue. Proteases were expressed by the majority of the tumors and normal breast tissues examined. ST3, gelatinase A and matrilysin mRNAs were more often expressed at high levels in carcinomatous than in normal breast tissues. Differences in the distribution of gelatinase B mRNA were not found. However, paired normal tissues generally produced weaker signals when compared to matched tumor samples. Univariate analysis showed no significant association of gelatinase A and matrilysin mRNAs with the classical prognostic markers (age, menopausal status, stage, size, nodal status, vascular infiltrate, necrosis, steroid receptors, metastasis and survival). Overexpression of ST3 was more frequently found in tumors of post-menopausal women (P < 0.022). Elevated expression of gel B mRNA was associated with the presence of vascular infiltrate (P < 0.026), necrosis (P < 0.039), PR negative tumors (P < 0.014) and inversely correlated to the number of survivors (P < 0.021). Multivariate analysis including 68 patients for whom all information was available indicated that neither stromelysin correlated significantly with pathological, clinical or biochemical features. High levels of gelatinase A and B mRNAs were inversely associated with the number of survivors. Our findings suggest that measurements of gelatinase A and B mRNAs expression in breast carcinoma may help to identify patients with an aggressive form of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9932604     DOI: 10.1023/a:1006580415796

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.

Authors:  H P Emonard; A G Remacle; A C Noël; J A Grimaud; W G Stetler-Stevenson; J M Foidart
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

2.  Characterization of mouse ribosomal gene fragments purified by molecular cloning.

Authors:  N Arnheim
Journal:  Gene       Date:  1979-10       Impact factor: 3.688

3.  Laminin receptors, collagenase IV and prognosis in node-negative breast cancers.

Authors:  M G Daidone; R Silvestrini; A D'Errico; G Di Fronzo; E Benini; A M Mancini; S Garbisa; L A Liotta; W F Grigioni
Journal:  Int J Cancer       Date:  1991-06-19       Impact factor: 7.396

4.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas.

Authors:  P Basset; J P Bellocq; C Wolf; I Stoll; P Hutin; J M Limacher; O L Podhajcer; M P Chenard; M C Rio; P Chambon
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

Review 5.  Metalloproteinases and their inhibitors in matrix remodeling.

Authors:  L M Matrisian
Journal:  Trends Genet       Date:  1990-04       Impact factor: 11.639

6.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

7.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.

Authors:  I E Collier; S M Wilhelm; A Z Eisen; B L Marmer; G A Grant; J L Seltzer; A Kronberger; C S He; E A Bauer; G I Goldberg
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

8.  Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue.

Authors:  C Monteagudo; M J Merino; J San-Juan; L A Liotta; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 9.  Stromelysin-3 in the biology of the normal and neoplastic mammary gland.

Authors:  M C Rio; O Lefebvre; M Santavicca; A Noël; M P Chenard; P Anglard; J A Byrne; A Okada; C H Régnier; R Masson; J P Bellocq; P Basset
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

10.  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.

Authors:  S M Wilhelm; I E Collier; B L Marmer; A Z Eisen; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

View more
  24 in total

Review 1.  Angiogenesis inhibitors.

Authors:  T R Tennant; C W Rinker-Schaeffer; W M Stadler
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe.

Authors:  Walter J Akers; Baogang Xu; Hyeran Lee; Gail P Sudlow; Gregg B Fields; Samuel Achilefu; W Barry Edwards
Journal:  Bioconjug Chem       Date:  2012-02-29       Impact factor: 4.774

3.  Nanoparticle self-assembly gated by logical proteolytic triggers.

Authors:  Geoffrey von Maltzahn; Todd J Harris; Ji-Ho Park; Dal-Hee Min; Alexander J Schmidt; Michael J Sailor; Sangeeta N Bhatia
Journal:  J Am Chem Soc       Date:  2007-04-21       Impact factor: 15.419

4.  Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression.

Authors:  M E Kupferman; M E Fini; W J Muller; R Weber; Y Cheng; R J Muschel
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo.

Authors:  Xuan Zhang; Jamee Bresee; Gregg B Fields; W Barry Edwards
Journal:  Bioorg Med Chem Lett       Date:  2014-07-05       Impact factor: 2.823

6.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

7.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

8.  Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer.

Authors:  Ayla Acar; Anil Onan; Ugur Coskun; Aytug Uner; Umit Bagriacik; Funda Atalay; Diclehan Kilic Unsal; Haldun Guner
Journal:  Med Oncol       Date:  2007-12-11       Impact factor: 3.064

9.  Genetic polymorphisms in the MMP-7 gene and breast cancer survival.

Authors:  Alicia Beeghly-Fadiel; Xiao-Ou Shu; Jirong Long; Chun Li; Qiuyin Cai; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

10.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.

Authors:  Andrea Köhrmann; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Jelena Anacker
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.